| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100 - 1/500 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | DTL; BAFF; BLYS; CD257; TALL1; THANK; ZTNF4; TALL-1; TNLG7A; TNFSF20 |
| Entrez GeneID | 10673 |
| clone | 6C3A2 |
| WB Predicted band size | 31.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TNFSF13B (AA: 116-278) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TNFSF13B(BAFF)抗体的3-4篇文献摘要概述：
1. **文献名称**：*"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial"*
**作者**：Navarra, S. V. 等
**摘要**：该III期临床试验表明，抗BAFF单抗贝利木单抗(Belimumab)可显著改善活动性系统性红斑狼疮(SLE)患者的疾病活动度，减少复发，且安全性良好，支持其作为首个靶向BAFF的生物制剂用于SLE治疗。
2. **文献名称**：*"TACI and BCMA are receptors for BAFF: identification of a third receptor for BAFF and interactions with APRIL"*
**作者**：Gross, J. A. 等
**摘要**：本研究揭示BAFF通过结合TACI和BCMA受体调控B细胞存活与成熟，为开发靶向BAFF/受体通路的抗体(如Belimumab)提供了分子机制基础，解释了其在治疗B细胞介导的自身免疫病中的作用。
3. **文献名称**：*"BAFF and selection of autoreactive B cells: new insights from mouse models"*
**作者**：Mackay, F. 等
**摘要**：通过小鼠模型研究，证实BAFF过表达导致自身反应性B细胞逃逸清除，促进自身免疫病发展。靶向BAFF的抗体可有效减少病理性B细胞，为治疗类风湿性关节炎等疾病提供理论依据。
4. **文献名称**：*"Targeting BAFF in autoimmunity"*
**作者**：Vincent, F. B. 等
**摘要**：综述总结了BAFF在自身免疫病中的核心作用，讨论抗BAFF抗体的临床进展(如Belimumab和Atacicept)，并指出其在调节异常B细胞活化中的治疗潜力及面临的挑战(如患者应答差异)。
这些文献涵盖了从基础机制到临床应用的TNFSF13B/BAFF抗体研究，涉及自身免疫病治疗的关键方向。
TNFSF13B, also known as B-cell activating factor (BAFF) or BLyS (B lymphocyte stimulator), is a member of the tumor necrosis factor (TNF) superfamily. It plays a critical role in B-cell survival, proliferation, and maturation by binding to receptors BAFF-R, TACI, and BCMA. Dysregulation of TNFSF13B is linked to autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjögren’s syndrome, where excessive B-cell activity drives autoantibody production.
Antibodies targeting TNFSF13B are designed to neutralize its activity, thereby suppressing pathogenic B-cell responses. Belimumab, a monoclonal antibody approved for SLE, is a prominent example that binds soluble TNFSF13B, blocking interactions with its receptors. These antibodies are valuable tools for both therapeutic and research applications, aiding in the study of B-cell biology and immune regulation. Additionally, TNFSF13B-targeting antibodies are explored in cancers, particularly B-cell malignancies, where aberrant BAFF signaling promotes tumor survival. Challenges include balancing efficacy with potential immunosuppression risks. Ongoing research focuses on optimizing antibody specificity and combination therapies to enhance clinical outcomes in autoimmune and oncological contexts.
×
